Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indoco Remedies has informed that United States Food and Drug Administration (USFDA) had inspected Company’s Sterile Facility (Plant II) located at Goa(‘Facility’), from February 20, 2023 to February 28, 2023. The said Facility had 4 observations in Form 483. USFDA has determined the inspection classification of this Facility as OAI (Official Action Indicated). The Company is committed towards working with USFDA for remediation of the concerns on highest priority.
The above information is a part of company’s filings submitted to BSE.
